
MD PhD FEBU - Urologist @ZAS_Ziekenhuis
Antwerp, Belgium
Joined May 2016
- Tweets245
- Following98
- Followers156
- Likes907
Filip Poelaert retweeted
🚨 Major shift: @AmericanCancer now directly recommends routine PSA screening for #prostatecancer, moving off pure shared decision-making 🚨
@CACancerJournal
📋 Average risk: PSA every 2 yrs, ages 50-69
📋 High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69
📋 Non-Black w/ one first-degree relative dx ≥65: every 2 yrs, ages 45-69
🔬 Age-adjusted elevated = PSA ≥3.0 (ages 45-69) or ≥6.5 (70-74); repeat in 2 wks to 3 mo, then MRI and/or validated biomarker before biopsy
🛑 70-74 individualized; not recommended ≥75 or if life expectancy <10 yrs
⚠️ Still requires informed consent on benefits, limits, and harms, and departs from USPSTF’s grade C for 55-69
🎯 ACS has moved from “discuss it” to “do it” for average-risk men 50-69 and high-risk men from 45, its biggest change since 2010
🔗 doi.org/10.3322/caac.70112
@UroOnc @urotoday @UrologyTimes @PCF_Science @AmerUrological
Filip Poelaert retweeted
Introducing my En bloc HoLEP Video Library.
Real cases, searchable by technique, prostate size and documented challenges. Free access, with an interface in 8 languages. Save the link below!
I hope it helps with your learning curve!
holep.icua.es/library/
#HoLEP #Urology
Filip Poelaert retweeted
Almost all high-income countries have a national policy recommending shared decision-making before PSA screening. We show: a) this recommendation never justified by evidence; b) best evidence is PSA screening not a preference-sensitive decision. journals.sagepub.com/eprint/…
Filip Poelaert retweeted
🚨 MRI-first screening w/o contrast finds more ≥GG2 #ProstateCancer 🚨
@EurUrol
👥 759 pts randomized
📊 Biparametric MRI first vs MRI only if PSA ≥3
⏱️ 15 min scan, no contrast
✅ csPCa detected: 4.6% vs 1.8% (RR 2.6, 95% CI 1.1-6.1)
✅ Several csPCa found in pts w/ normal PSA
⚠️ More biopsies in MRI-first arm (10.8% vs 5.2%)
🎯 A FAST⚡️ contrast-free MRI up front catches significant PCa a PSA screen might miss
@PCF_Science @PCFnews @urotoday @UrologyTimes @UroOnc
🔗shorturl.at/NUI1i
Filip Poelaert retweeted
Generally assumed population-based PSA screening = increased overdiagnosis. But already lots of PSA testing going on. In a modeling study, we show organized screening would reduce PSA tests, overdiagnosis compared to current disorganized approach
onlinelibrary.wiley.com/doi/…
Original Article: Perioperative Apalutamide in High-Risk Localized Prostate Cancer (phase 3 PROTEUS trial) nej.md/3RuNe00
Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer nej.md/4dLeiiW
#Oncology #Urology

ALT This image contains four graphs showing the key secondary end points. Graph A shows event-free survival over time in months since randomization comparing ADT plus apalutamide and ADT plus placebo. Graph B presents the first subsequent local or systemic therapy occurrence, with the same treatment comparison. Graph C illustrates distant metastasis or conventional imaging or PSMA PET. Graph D compares freedom from disease at four years with percentages for both treatment groups. Each graph includes shaded confidence intervals and hazard ratios with confidence intervals.
Filip Poelaert retweeted
🚨 177Lu-PSMA-617 to ADT + ARPI improves rPFS (PSMAddition) 🚨
@TheLancet
👥 1144 pts w/ PSMA+ metastatic APMN/S #ProstateCancer (50% de novo, 68% high-volume)
📊 Phase 3 RCT, 1:1, open-label, 169 sites, crossover allowed at progression
💊 177Lu-PSMA-617 (7.4 GBq q6w x6) + ADT/ARPI vs ADT/ARPI
⏱️ Median f/u 19.6 mo for rPFS
✅ rPFS HR 0.72 (95% CI 0.58-0.90), p=0.0021; median not reached in either arm
BUT👇
⚠️ G3+ AEs 51% vs 43%; dry mouth 46% vs 4% (all G1-2); more cytopenias and GI events
⚠️ QoL trended worse w/ RLT: time to FACT-P worsening 11.3 vs 17.1 mo (HR 1.14, CI crosses 1); gap seen mainly during treatment cycles, similar arms after week 36
🎯 RLT moves into earlier stage PCa. But we need to keep an eye on QoL
@AmerUrological @UroOnc @SUO_YUO @PCFnews @urotoday @UrologyTimes @PCF_Science
🔗shorturl.at/yGNAS
Filip Poelaert retweeted
🚨active surveillance, for #prostatecancer, now with a 25-year horizon🚨
@EUplatinum
📊 GÖTEBORG-1, screen-detected low- and intermediate-risk PCa, f/u up to 25 yrs
✅ extended data continue to support AS as safe for well-selected pts over the very long term
⚠️ intermediate-risk selection and adherence to follow-up still matter, this is screen-detected disease
⭐️PCa-specific survival at 25 yrs was 94%
-99% for VLR
-92% for LR
-85% for Int Risk
🎯 bottom line: when we tell a pt w/with low-risk PCa that surveillance is safe, we can now point to a quarter century of trial follow-up.
🔗 shorturl.at/H2a6x
#pcsm @AmerUrological @UroOnc @GGiannarini @PCFnews @PCF_Science @GabeCanales @ASPI_INTL
Filip Poelaert retweeted
🧇Please feel free to use our patient-facing "waffles" for joint decision making in clinic siancooper.github.io/PACE-B-…
Filip Poelaert retweeted
Zo wil het RIZIV de artsenhonoraria opsplitsen: 65% intellectueel, 35% praktijkkosten - despecialist.eu/nl/nieuws/be… @bvastweets @ASGB_KARTEL @GevaertThomas @dr_wardsam @DeClercqLuc @BOVYN
Filip Poelaert retweeted
Thomas Gevaert slaat alarm over splitsing honorarium: "Arts blijft geen eigenaar van het kostendeel” - despecialist.eu/nl/nieuws/th… @ASGB_KARTEL @GevaertThomas
Filip Poelaert retweeted
Marc Moens over de splitsing van het honorarium: “Ik vrees dat de artsen in een valstrik zijn getrapt” - despecialist.eu/nl/nieuws/be… @MarcMoens50 @bvastweets @ASGB_KARTEL
Filip Poelaert retweeted
🔥 POISE-3 Urology published in European Urology 🚨
In the largest randomized placebo-controlled #urology analysis of #TranexamicAcid (TXA), #TXA reduced major #bleeding risk by 37% (from 9.5% to 6.1%) with no clear increase in #thrombosis
More at sciencedirect.com/science/ar…
#EBM
Filip Poelaert retweeted
#SESAUA26 State of the Art Lecture @sanojpunnen
PCa Screening Guidelines:
♦️Start: 45-50 yrs
♦️Screen q2-4 yrs if PSA < 1
♦️Screen q1-2 yrs if PSA >1
♦️Intervene: PSA 3-4
♦️Stop: 70-75 yrs or life expectancy < 10 yrs
@urotoday
Filip Poelaert retweeted
Impact of 1g Tranexamic Acid on Outcomes in EEP Patients
🩸 Reduced bleeding complications with TXA (OR 0.17)
⏲ Shortest hemostasis time with TXA (p < 0.001)
📈 Higher bleeding risk on blood thinners (OR 2.93)
@DocGauhar @trwherrmann @ytanidir @drabhaymahajan @doc_sarvajit @endouro @D_Castellani @steffiyuen
Filip Poelaert retweeted
🌍 Global patient reported outcomes (PROs) after localized #ProstateCancer treatment
👇New data from 27,499 patients across 16 countries (TrueNTH Registry)
Big predictors
🏁 Baseline function matters most
🏥 Treatment modality drives domain-specific tradeoffs
12-mo outcomes
🔴 RP → ↓ urinary continence & sexual function
📡 EBRT + ADT → ↓ bowel & hormonal function
🟢 AS → smallest functional declines
Reality check
⚠️Global models explain only ~14–32% of variance
🌐 Major regional heterogeneity → one-size models fall short
🎯 Takeaway
Personalized counseling needs baseline function + local context, not just treatment labels
🔗shorturl.at/bjBcf
@UCLAHealthJCCC @UclaUrology @CS_Urology @CSCancerCenter @UrologyTimes @PCFnews @renalandurology @urotoday
Filip Poelaert retweeted
🚨 New ESMO guideline on localized & locoregional prostate cancer! annalsofoncology.org/article…
💥 Clear algorithms for diagnosis, risk stratification & treatment
🎯 Active surveillance where appropriate & escalation when needed
🤝 Multidisciplinary (evidence-based) globally aligned
Good oncology isn’t about doing more…it’s about doing it right!!
Congrats to @AttardLab @Ecastromarcos @stefanofanti4 @Silke_Gillessen @Prof_Nick_James @piet_ost @MarkARubin1 @ChrisSweens1 @Tilki_De @ZilliThomas @alison_tree and all the team! 👏🏼
@OncoAlert #OncoAlertAF @OncoReporte @myESMO @_SEOM
Filip Poelaert retweeted
PSA for Prostate Cancer Screening: How ERSPC confirms the importance of active surveillance open.substack.com/pub/beyond…
Filip Poelaert retweeted
🤖🆚🗡️ Robotic vs open partial nephrectomy for complex kidney tumors
👏Tested in an RCT (OpeRa trial)
@Annals_Oncology
🔑🔑 Takeaways:
⚖️ 30-day complications: no significant difference (RAPN 37% vs OPN 46%)
⏱️ RAPN = longer OR + warm ischemia time
🏥 RAPN = shorter hospital stay
💊 Less opioids, less pain
😊 Better QoL through POD30
⭐️ RAPN not clearly safer, but easier on patients in the short term — even for intermediate/high-complexity tumors
🔗shorturl.at/dUbgk
@urotoday @renalandurology @UrologyTimes
Filip Poelaert retweeted
Hoeveel verdienen ASO’s na indexering? - despecialist.eu/nl/nieuws/be… @TweetsVaso @bvastweets @ASGB_KARTEL



































